stockrowiSpecimen Inc.
ISPC Healthcare Diagnostics & Research
iSpecimen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, down 79.2% from fiscal 2024.
- Revenue
- −78.7%
- EPS
- +94.2%
- Free cash flow
- −257.7%
Quarter to June 2026, against a year earlier
Follow ISPC
Alert me
iSpecimen Inc. (ISPC) EV/Sales
As of 5 November 2026, iSpecimen Inc. (ISPC) trades at a EV/Sales of −1.5×. Over the past ten years it has ranged from −1.6× (March 2026) to 12.0× (November 2021); the current reading is higher than 1% of that period. That is below the Diagnostics & Research industry median of 5.2× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −1.2× | — |
| FY2024 | 0.4× | 69.76% |
| FY2023 | 0.2× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.8× | (54.84%) |
| FY2020 | 1.9× | 0.00% |
| FY2019 | 1.9× | 0.00% |
| FY2018 | 1.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.1× | 115.20% |
| Mar 2026 | 1.9× | — |
| Dec 2025 | −1.2× | — |
| Sep 2025 | 2.2× | 191.22% |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DMTKQ DermTech, Inc. compare | −2.5× |
| ISPC iSpecimen Inc. | −1.5× |
| BIAF bioAffinity Technologies, Inc. compare | −0.2× |
| XWEL XWELL, Inc. compare | −0.1× |
| ADVB Advanced Biomed Inc. compare | n/m |
| AWHL Aspira Women's Health Inc. compare | 1.2× |
| PRPH ProPhase Labs, Inc. compare | 1.8× |
| NDRA ENDRA Life Sciences Inc. compare | 1.9× |
| TTOO T2 Biosystems, Inc. compare | 6.3× |
| Diagnostics & Research industry median | 5.2× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)